Medicamen Biotech Ltd

Know More

607.603.70 (0.61%)

12:00 AM,8th Dec 2023

607.451.85 (0.31%)

12:00 AM,8th Dec 2023

BSE : 531146


Sector : Health care

ISIN Code : INE646B01010

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Dec 08 2023 | 12:00 AM IST

Market Cap (₹ Cr)


Turnover (₹ Cr)


Volume (Shares)


Face Value


52-WK High


52-WK High Date

15 Dec 2022

52-WK Low


52-WK Low Date

26 Oct 2023

All Time High


All Time High Date

01 Sep 2022

All Time Low


All Time Low Date

29 Oct 2021

Medicamen Biotech Ltd

Medicamen Biotech Ltd is a widely held Globally Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. The company is engaged in manufacture and distribution of medicines. They manufacturer and supply the range of products such as tablets capsules liquid syrup and dry syrup (beta lactum and non beta lactum) and ointment. The company has two manufacturing facilities namely Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit the company manufactures Non-Betalactum preparations including tablets capsules oral liquids and ointments & creams.The company is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical Fraternity.Medicamen Biotech Ltd was incorporated on December 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted the company to go for own manufacturing facilities. Thus in the year 1994 a land of 210000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured. In the year 1995 the company was enlisted in Bombay Stock Exchange.In the year 2005 the company installed the second unit in the tax free zone at Haridwar in Uttarakhand keeping the space with the ever increase in demand and fulfilling the commitment.During the year 2006-07 the company added Analgesic and Anti bacterial Anti filarial and Anti TB products in its range and done two mega projects of Govt. of India related to Anti filarial and Anti TB drugs. They also supplied Anti bacterial products like Cotrimoxazole and Anti Analgesics like Paracetamol in bulk to their foreign partners. During the year the company increased the production capacity of Tablets by 600 lakh Nos to 7800 lakh Nos.The second unit in Haridwar became fully operational from April 2007 with ultra modern manufacturing facilities comprises of Non Betalactum Tablets Capsules oral liquids & ointments with the production capacity of 4100 lakh Nos 600 lakh Nos 6 lakh Litre and 0.30 lakh kg respectively. The company upgraded the Bhiwadi unit with a consolidated cost of more than Rs 2.5 crore under the latest WHO guidelines on CGMP.'The Company launched the marketing division in Jan'09 with 16 products in Delhi & Uttrakhand regions. On September 16 2015 M/s. Shivalik Rasayan Limited (Acquirer) got into two Share Purchase Agreements(SPAs) with Promoters of the Company - SPA 1 with Mr. Bal Kishan Gupta Mr. Ashutosh Gupta Ms. Ritu Gupta Ms. Suchita Gupta and SPA 2 with Mr. Abhishek Bansal Ms. Manju Bansal Mr. Sanjay Bansal and Ms. Ayushi Bansal for the acquisition of 4412095 fully paid-up Equity Shares of Rs.10/- each representing 44.15% of the paid up equity share capital of the Company through which the Acquirer made a Takeover Open Offer Transaction to acquire 26% of the Paid up Capital of the Company which was completed in December 2015 and the Acquirer became New Promoter of the Company.The Company acquired 100% stake of OPAL Pharmaceuticals Pty Ltd from its existing shareholder aggregating upto (AUD) $420000 in 2019-20. OPAL a wholly owned subsidiary of the Company merged with the Company effective September 17 2019. The Company has launched 12 Oncology products in domestic market effective from January 2022.

Medicamen Biotech Ltd - Key Fundamentals

Market Cap (₹ Cr)


EPS - TTM (₹) [S]


P/E Ratio (X) [S]


Face Value (₹) 10
Latest Dividend (%)10.00
Latest Dividend Date 20 Sep 2023
Dividend Yield (%) 0.16
Book Value Share (₹) [S]159.06
P/B Ratio (₹) [S]3.82
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
Motilal Oswal S&P BSE Healthcare ETF 0.00 57 0.05

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High



Week Low/High



Month Low/High



Year Low/High



All time Low/High



Share Price Returns

1 Week-4.12%-3.94%3.473.46%
1 Month-9.27%-9.21%7.467.85%
3 Month-13.19%-13.04%4.845.80%
6 Month-9.68%-9.67%11.1012.53%
1 Year-28.52%-28.48%11.5912.68%
3 Year52.41%%53.1056.57%

Company Info

Company Information

Director : Sanjay Bansal

Chairman (Non-Executive) : Rahul Bishnoi

Director : Ashwani Kumar Sharma

Independent Director : Harish Pande

Director : S K Singh

Independent Director : Arun Kumar

Company Sec. & Compli. Officer : Parul Choudhary

Independent Director : Sumita Dwivedi

Director : Vimal Kumar Shrawat.

Independent Director : Sangeeta Bishnoi

Independent Director : Ravi Kumar Bansal

Registered Office: 1506 Chiranjiv Tower 43, Nehru Place,New Delhi,New Delhi-110019 Ph: 91-11-47589500